| Literature DB >> 33230288 |
Franciele Cristina Kipper1,2,3, Cleide Angolano4,2,3, Ravi Vissapragada1,5, Mauricio A Contreras6, Justin Moore1,3, Manoj Bhasin7, Christiane Ferran4,6,2,3, Ajith J Thomas8,9,10.
Abstract
Brain embryonic periventricular endothelial cells (PVEC) crosstalk with neural progenitor cells (NPC) promoting mutual proliferation, formation of tubular-like structures in the former and maintenance of stemness in the latter. To better characterize this interaction, we conducted a comparative transcriptome analysis of mouse PVEC vs. adult brain endothelial cells (ABEC) in mono-culture or NPC co-culture. We identified > 6000 differentially expressed genes (DEG), regardless of culture condition. PVEC exhibited a 30-fold greater response to NPC than ABEC (411 vs. 13 DEG). Gene Ontology (GO) analysis of DEG that were higher or lower in PVEC vs. ABEC identified "Nervous system development" and "Response to Stress" as the top significantly different biological process, respectively. Enrichment in canonical pathways included HIF1A, FGF/stemness, WNT signaling, interferon signaling and complement. Solute carriers (SLC) and ABC transporters represented an important subset of DEG, underscoring PVEC's implication in blood-brain barrier formation and maintenance of nutrient-rich/non-toxic environment. Our work characterizes the gene signature of PVEC and their important partnership with NPC, underpinning their unique role in maintaining a healthy neurovascular niche, and in supporting brain development. This information may pave the way for additional studies to explore their therapeutic potential in neuro-degenerative diseases, such as Alzheimer's and Parkinson's disease.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33230288 PMCID: PMC7683543 DOI: 10.1038/s41598-020-77297-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Baseline expression profile of PVEC and ABEC highlights the distinct identity of these vascular beds. (a) Hierarchical clustering indicates total segregation between PVEC and ABEC. (b) Heatmap of the top 50 genes that were significantly different in PVEC vs. ABEC, based on fold change. Red indicates genes with higher expression and blue indicates genes with lower expression in PVEC vs. ABEC. (c) Volcano plot encompassing all analyzed genes, depicted as dots. Black dots represent genes that were not significantly different, while gray dots represent genes that were significantly different in PVEC vs. ABEC, based on fold change (FC) > 2 and p-value < 0.05. Highlighted in blue dots are the genes that were most significantly lower, and in red dots genes that were most significantly higher in PVEC vs. ABEC.
Figure 2GO analysis identifies nervous system development and response to stress as the processes with the greatest number of DEG that were higher or lower in PVEC vs. ABEC. (a) Gene Ontology (GO) analysis using the Metacore from Clarivate Analytics identified the top 5 most enriched biological process when separated by higher (red) or lower (blue) differentially expressed genes (DEG) in PVEC vs. ABEC. (b) The top 10 more enriched biological processes when all DEG were analyzed together closely resembles the analysis performed using DEG that were higher in PVEC vs. ABEC. Numbers inside the bars correspond to the number of DEG in each given GO biological process. (c) Canonical pathway enrichment analysis using the Metacore identified the top 10 most enriched pathways in PVEC vs. ABEC, here depicted as grey bars. Numbers inside the bars correspond to the number of DEG that were identified in each given pathway. (d) Canonical pathway enrichment using the Metacore, following partitioning of our data into genes that were higher (red) or lower (blue) in PVEC vs. ABEC identified the top 10 pathways in each category.
Differentially expressed genes in the “transcription: HIF-1 targets” pathway.
| Process | Gene | Fold change | p-value |
|---|---|---|---|
| Angiogenesis | VEGF-A | 10.14 | 1.15E−11 |
| α1B adrenergic receptor | 7.34 | 5.64E−05 | |
| Angiopoietin 2 | 4.79 | 3.73E−09 | |
| Thrombospondin 1 | 4.40 | 6.40E−08 | |
| PAI | 4.09 | 9.08E−08 | |
| Adrenomedullin | 2.71 | 1.01E−07 | |
| FGF2 | 2.32 | 4.14E−02 | |
| MGF | − 8.36 | 1.70E−10 | |
| PLGF | − 8.52 | 1.77E−09 | |
| VEGFR-1 | − 11.05 | 2.45E−09 | |
| Endoglin | − 13.70 | 2.62E−11 | |
| SDF-1 | − 14.11 | 1.21E−11 | |
| Glucose metabolism | GLUT3 | 421.30 | 1.27E−06 |
| ALDOC | 74.49 | 6.35E−09 | |
| HXK2 | 16.55 | 4.62E−09 | |
| F263 | 2.87 | 7.85E−08 | |
| MCT4 | 2.00 | 1.35E−04 | |
| HXK1 | − 2.32 | 9.61E−09 | |
| PGK1 | − 2.43 | 2.08E−07 | |
| PFKL | − 2.43 | 3.17E−09 | |
| PDK1 | − 2.45 | 2.25E−07 | |
| ENO1 | − 903.94 | 2.56E−13 | |
| Extracellular matrix remodeling | Lysyl oxidase | 638.91 | 7.68E−05 |
| MMP-2 | 83.05 | 9.41E−10 | |
| LOXL2 | 20.82 | 4.43E−11 | |
| P4HA2 | − 2.11 | 3.84E−08 | |
| PLAUR | − 3.36 | 1.31E−08 | |
| LOXL4 | − 18.11 | 6.34E−09 | |
| Fibrosis immuno-regulation | TGF-beta3 | 33.51 | 7.20E−11 |
| CTGF | 15.95 | 1.36E−09 | |
| TGF-beta2 | 9.03 | 1.27E−08 | |
| TGF-beta1 | − 3.38 | 1.34E−08 | |
| Stem cell maintenance | SOX2 | 708.34 | 6.72E−06 |
| Oct-3/4 | − 9.17 | 6.98E−04 | |
| NANOG | − 9.57 | 8.78E−08 | |
| Cell cycle arrest | p21 | 2.10 | 1.15E−08 |
| c-Myc | -2.01 | 3.59E−07 | |
| Chemotaxis | CXCR4 | 400.55 | 3.39E−09 |
| CX3CR1 | 3.17 | 1.35E−02 | |
| Transcription regulation | ROR-alpha | 100.74 | 1.49E−08 |
| ID2 | 2.31 | 1.84E−08 | |
| Nucleotide metabolism | AK3 | 3.84 | 1.09E−07 |
| Nt5e | − 2.03 | 7.39E−05 | |
| Iron ion metabolism | Ceruloplasmin | 80.37 | 9.94E−12 |
| Transferrin | 61.58 | 4.14E−08 | |
| Regulation of pH | Carbonic anhydrase IX | 11.86 | 2.17E−04 |
| Lipid metabolism | A2M/LRP1 | 10.40 | 2.67E−08 |
| Amino acid metabolism | TGM2 | − 3.85 | 3.99E−08 |
| Negative regulation of HIF1A signaling | CITED2 | 3.61 | 5.16E−10 |
| Regulation of cell proliferation | IBP3 | 16.22 | 1.35E−10 |
| Apoptosis | NOXA | 729.95 | 7.75E−08 |
| Heme metabolism | FECH | 2.42 | 5.43E−09 |
| Other | MDR1 | − 124.65 | 1.32E−11 |
List of transcripts DEG sorted by process and fold change, with respective p-value when compared PVEC vs. ABEC.
Differentially expressed genes involved in the WNT signaling pathway.
| Family | Gene | Fold change | p-value |
|---|---|---|---|
| Wingless-type MMTV integration site family | Wnt7a | 69.05 | 9.66E−08 |
| Wnt8b | 22.64 | 2.65E−08 | |
| Wnt2b | 13.46 | 3.66E−08 | |
| Wnt2b | 13.46 | 3.66E−08 | |
| Wnt7b | 12.13 | 5.17E−07 | |
| Wnt3 | 11.21 | 3.83E−08 | |
| Wnt3 | 11.21 | 3.83E−08 | |
| Wnt2 | 11.21 | 6.94E−05 | |
| Wnt2 | 11.21 | 6.94E−05 | |
| Wnt9a | 8.16 | 4.57E−10 | |
| Wnt9a | 8.16 | 4.57E−10 | |
| Wnt5b | 7.15 | 2.02E−07 | |
| Wnt5a | 5.34 | 5.90E−10 | |
| Wnt5a | 5.34 | 5.90E−10 | |
| Wnt4 | 2.37 | 6.04E−06 | |
| Wnt4 | 2.37 | 6.04E−06 | |
| Frizzled | Fzd1 | 599.47 | 6.89E−07 |
| Fzd3 | 226.56 | 1.75E−08 | |
| Fzd2/10 | 78.70 | 1.80E−10 | |
| Fzd7 | 3.05 | 1.23E−07 | |
| Fzd8 | 2.69 | 5.28E−08 | |
| Fzd9 | − 14.35 | 6.01E−10 | |
| Fzd4 | − 18.05 | 7.14E−11 | |
| Tcf(Lef) | Lef1 | 63.82 | 2.17E−08 |
| Tcf7 | 17.06 | 7.81E−09 | |
| Tcf7l2 | 2.03 | 7.89E−09 | |
| Tcf7l2 | 2.03 | 7.89E−09 | |
| p38 MAPK | Mapk13 | 25.61 | 1.40E−05 |
| Mapk11 | − 8.81 | 3.56E−09 | |
| Mapk12 | − 16.20 | 7.54E−11 | |
| Dishevelled segment polarity protein (DSH) | Dvl3 | 2.95 | 1.08E−08 |
| Dvl2 | 2.23 | 1.52E−07 | |
| Dvl1 | 2.01 | 4.97E−07 | |
| Secreted frizzled-related protein | Sfrp1 | 501.83 | 3.66E−08 |
| Sfrp2 | 5.34 | 1.21E−06 | |
| Dickkopf WNT signaling pathway inhibitor | Dkk3 | 853.00 | 1.07E−09 |
| Axin2 | Axin2 | 166.70 | 1.30E−08 |
| BMI-1 | Bmi1 | − 2.35 | 1.46E−08 |
| Inhibitor of growth family | Ing4 | 2.21 | 5.33E−08 |
| Other | hASH1 | 175.40 | 3.60E−10 |
| NKD1 | 117.22 | 9.19E−07 | |
| ROR2 | 100.74 | 1.49E−08 | |
| WIF1 | 71.26 | 5.31E−08 | |
| NOTCH3 | 70.10 | 1.21E−08 | |
| VEGF-A | 10.14 | 1.15E−11 | |
| Porcn | 8.42 | 1.70E−07 | |
| Krm1 | 2.56 | 1.39E−08 | |
| p21 | 2.10 | 1.15E−08 | |
| c-Myc | − 2.01 | 3.59E−07 | |
| Survivin | − 2.38 | 4.90E−08 | |
| Oct-3/4 | − 9.17 | 6.98E−04 |
List of transcripts DEG in the WNT pathway sorted by family/function, and its respective fold change and p-value when compared PVEC vs. ABEC.
Differentially expressed SLC transporters in PVEC vs. ABEC.
| Gene | Fold change | Protein name | Substrates | Family |
|---|---|---|---|---|
| Slc1a3 | 1465.89 | EAAC1, EAAT1 | L-Glu, D/L-Asp | High-affinity glutamate and neutral amino acid transporter |
| Slco1c1 | 654.22 | OATP1C1 | T4, T3, rT3 | Organic anion transporter |
| Slc2a3 | 489.48 | GLUT3 | Glucose, galactose, mannose, xylose | Facilitative GLUT transporter |
| Slc4a3 | 295.16 | AE3 | Chloride bicarbonate | Bicarbonate transporter |
| Slc6a15 | 280.17 | NTT73 | Large, neutral amino acids | Sodium- and chloride-dependent neurotransmitter transporter |
| Slc16a9 | 247.31 | MCT9 | Monocarboxylate transporter | |
| Slc25a23 | 236.53 | APC2 | ATP-Mg2+, ATP, ADP, AMP, Pi | Mitochondrial carrier |
| Slco1a5 | 170.64 | OATP-3 | Taurocholate and thyroid hormones | Organic anion transporter |
| Slc39a12 | 140.97 | ZIP12j, LZT-Hs8 | Zn | Metal ion transporter |
| Slc16a2 | 131.42 | MCT8 | T2, rT3, T3, T4 | Monocarboxylate transporter |
| Slc38a3 | 130.64 | SNAT3 | Q, H, A, N | System A and System N sodium-coupled neutral amino acid transporter |
| Slc4a4 | 108.59 | NBCe1 | Sodium bicarbonate (and/or carbonate) | Bicarbonate transporter |
| Slc7a2 | 107.45 | CAT-2 (A or B) | Cationic | Cationic amino acid transporter/glycoprotein-associated |
| Slc15a2 | 98.45 | PEPT2 | Di- and tri-peptides, protons, beta-lactam antibiotics | Proton oligopeptide cotransporter |
| Slc6a1 | 76.36 | GAT-1 | GABA | Sodium- and chloride-dependent neurotransmitter transporter |
| Slc6a17 | 73.98 | NTT4 | Neutral amino acids | Sodium- and chloride-dependent neurotransmitter transporter |
| Slc2a13 | 73.70 | HMIT | Myo-inositol | Facilitative GLUT transporter |
| Slc1a2 | 69.88 | EAAC1, EAAT3 | L-Glu, D/L-Asp | High-affinity glutamate and neutral amino acid transporter |
| Slc24a3 | 69.45 | Na+/K+/Ca2+-exchange protein 3 | Na+/(Ca2+-K+) exchange | |
| Slc22a18 | 0.0154 | ORCTL-2 | Probably organic anions | Organic cation/anion/zwitterion transporter |
| Slc6a3 | 0.0124 | DAT | Dopamine | Sodium- and chloride-dependent neurotransmitter transporter |
| Slc16a11 | 0.0106 | MCT11 | Pyruvate | Monocarboxylate transporter |
| Slc46a3 | 0.0102 | Lysosomal export of maytansine conjugates | Folate transporter family | |
| Slc24a1 | 0.0096 | NCKX1 | Na+, Ca2+, K+ | Na+/(Ca2+-K+) exchange |
| Slc9b1 | 0.0015 | NHE1 | Na+, Li+, H+, NH4+ | Na+/H+ exchanger |
List of SLC family transcripts whose expression was at least 70-fold higher or lower in PVEC vs. ABEC.
Figure 3Comparative transcriptomic analysis of PVEC vs. ABEC following co-culture with NPC indicate major changes in PVEC not ABEC. (a) Principal component analysis (PCA) of transcriptome. Colors of circles refer to the origin of samples: green PVEC and purple ABEC, light versus dark shades indicate mono vs. NPC co-culture conditions. (b) Venn Diagram of DEG in PVEC vs. ABEC (grey ellipse), PVEC + NPC vs. ABEC + NPC (orange ellipse), ABEC vs. ABEC + NPC (pink ellipse) and PVEC vs. PVEC + NPC (blue ellipse). (c) Eight different self-organizing maps (SOM) patterns of gene expression profiles were identified amongst the 321 genes that were different in PVEC vs. PVEC + NPC and also in PVEC vs. ABEC. The upper panels display patterns whose gene expression is upregulated in PVEC + NPC as compared to baseline PVEC. Data is shown as standard boxplots (box and whisker plots), depicting the median bar and the dots representing the outliers. Lower panels depict patterns whose gene expression is downregulated in PVEC + NPC as compared to baseline PVEC. Treemap representation of GO_bp (biological process) using REVIGO (reduced visualization of GO) corresponding to (d) Pattern I, (e) Pattern VI and (f) Pattern VIII.
Figure 4PVEC exhibit a distinct gene signature independent from culture condition. Hierarchical clustering and heatmap analysis of the top 15 DEG in PVEC (n = 6) vs. ABEC (n = 8). Gene expression is shown in a pseudocolor scale. Red indicates genes with higher expression and blue indicates genes with lower expression in PVEC vs. ABEC.
Figure 5Canonical pathway enrichment analysis identifies immune response classical complement pathway as the ones most enriched in PVEC co-cultured with NPC. (a) Canonical pathway enrichment using the Metacore from Clarivate Analytics identified the top 10 most enriched pathways in PVEC vs. PVEC + NPC. (b) Depiction of the top most modified pathway, “Immune response: Classical complement pathway”. The legend included in the figure decodes the colored shapes and arrows used in the picture. Colored bars close to each protein name indicates whether the DEG was upregulated (red) or down-regulated (blue) upon co-culture of PVEC with NPC.